Keio Innovation Initiative has made an additional investment from a fund managed by our company in the Keio University School of Medicine start-up company, Celusion. The total amount raised in this round is approximately 360 million yen.

Cellusion is engaged in the development of cell therapy using iPS cell-derived corneal endothelial replacement cells for the treatment of bullous keratopathy. The company has recently raised funds from several investors to conduct clinical studies to confirm the safety of the product in humans. With this funding, Cellusion will further accelerate its research and development for social implementation of corneal endothelial regenerative medicine.

For more details, please refer to Cellusion’s press release.

Go to Cellusion’s website